Non-use of romosozumab |
4,097 / 701,204 (0.6) |
11.5 (8.58–15.2) |
<0.01 |
Use of romosozumab |
55 / 868 (6.3) |
|
|
Non-use of oral bisphosphonate |
4,064 / 685,957 (0.6) |
0.94
(0.76–1.16) |
0.64 |
Use of oral bisphosphonate |
90 / 16,115 (0.6) |
|
|
Non-use of teriparatide |
4,125 /
699,359 (0.6) |
1.82 (1.22–2.63) |
<0.01 |
Use of teriparatide |
29 / 2,713 (1.1) |
|
|
Non-use of denosumab |
4,140 / 697,883 (0.6) |
0.56 (0.31–0.94) |
0.03 |
Use of denosumab |
14 / 4,189 (0.3) |
|
|
|
Onset of cerebrovascular
events / Total, n (%)
|
Reporting odds ratio
(95% confidence interval)
|
P-value*
|
Non-use of romosozumab |
9,176 / 701,204 (1.3) |
7.03 (5.46–8.93) |
<0.01 |
Use of romosozumab |
74 / 868 (8.5) |
|
|
Non-use of oral bisphosphonate |
9,130 / 685,957 (1.3) |
0.56
(0.46–0.67) |
<0.01 |
Use of oral bisphosphonate |
120 / 16,115 (0.7) |
|
|
Non-use of teriparatide |
9,217 / 699,359 (1.3) |
0.92 (0.63–1.30) |
0.74 |
Use of teriparatide |
33 / 2,713 (1.2) |
|
|
Non-use of denosumab |
9,233 / 697,883 (1.3) |
0.30 (0.18–0.49) |
<0.01 |
Use of denosumab |
17 / 4,189 (0.4) |
|
|